Ignite Creation Date:
2024-05-06 @ 1:28 PM
Last Modification Date:
2024-10-26 @ 1:14 PM
Study NCT ID:
NCT04031885
Status:
TERMINATED
Last Update Posted:
2021-08-24
First Post:
2019-07-23
Brief Title:
A Study of Abemaciclib LY2835219 in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive HER2 Negative Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-08-14
Start Date Type:
ACTUAL
Primary Completion Date:
2020-08-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-08-11
Completion Date Type:
ACTUAL
First Submit Date:
2019-07-23
First Submit QC Date:
July 23 2019
Study First Post Date:
2019-07-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-08-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-29
Last Update Post Date:
2021-08-24
Last Update Post Date Type:
ACTUAL